NCT05154240View on ClinicalTrials.gov

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

INS018_055

INS018\_055 is a small molecule compound. INS018\_055 has good solubility in water and was chemically and physically stable at different temperatures.

DRUG

Placebo

Placebo

Trial Locations (1)

8011

NZCR Ltd, Christchurch

All Listed Sponsors
lead

InSilico Medicine Hong Kong Limited

INDUSTRY